HemoCue Hb 301血红蛋白分析仪在献血者筛查中的适用性分析

目的分析比较HemoCue Hb 301血红蛋白分析仪在献血者筛查中的适用性。方法随机选取街头60例献血者血样本使用HemoCue Hb 301血红蛋白分析仪和全自动血细胞分析仪检测血红蛋白(Hb),以全自动血细胞分析仪结果为参考,进行比较分析;取医院体检人群30个中轻度贫血的标本用HemoCue Hb 301血红蛋白分析仪检测Hb与全自动血细胞分析仪的结果进行比对分析;在街头献血者初筛中试用一段时间与传统的硫酸铜比重目测法进行比较。结果 HemoCue Hb301血红蛋白分析仪检测结果与Sysmex-kx 21N全自动血细胞分析仪比较,无统计学意义。献血者和中轻度贫血的批内精密度为0.74%和1.08%。硫酸铜比重目测法献血者淘汰率为2.05%,HemoCue Hb 301血红蛋白分析仪检测献血者淘汰率为2.39%。结论 HemoCue Hb 301血红蛋白分析仪批内精密度和准确度高,偏倚度可接受,操作轻便、快速、容易标准化,能准确定量献血者的Hb含量,数据可查,更符合血站质量管理规范的要求。很适合于街头献血者的初筛,尤其是以集体献血模式为主的采供血机构。     

在无偿献血者健康检查中开展血红蛋白定量检测的探讨

目的探讨在无偿献血者健康检查中开展血红蛋白定量检测的可行性。方法实验人群经硫酸铜（CuSO4）目测法检测血红蛋白（Hb）后，应用干式化学法对血液样本进行定量检测，同时应用血细胞计数仪检测加以验证，并对结果进行综合分析。结果干式化学法和血球计数仪法定量检测血红蛋白的差异无统计学意义，相关性较好。结论定量法检测血红蛋白能很好地解决硫酸铜目测法筛查献血者血红蛋白水平的不足，可以作为硫酸铜目测法筛查无偿献血者血红蛋白的一项有益补充。     

硫酸铜比重法在献血者献血前血红蛋白筛检中的价值

目的探讨硫酸铜比重法与干化学法两种血红蛋白检测法在献血者筛检中的应用价值,为采供血机构制定献血者血红蛋白筛检策略提供参考。方法采血前,采用硫酸铜比重法对献血者作血红蛋白筛检,对筛检判断不达标者,用Hemo Cue Hb 201+分析仪(干化学法)进行复检,记录相关数据。结果本采血点5577人次(男性4081,女性1496)献血者中,比重法筛检不达标者78例(男4例,占男性受检者的0.98‰,女74例,占女性受检者的4.95%);对78例比重法检测判定为不达标者进行干化学法复检,有57例未达到献血标准(女性血红蛋白115者53例,男性血红蛋白125者4例,女性受检者的不合格率由4.95%降至3.54%)。结论与用比重法相比,采用干化学法对进行血红蛋白筛检,女性献血者的合格率有所提高,但差异无统计学意义(P0.05)。比重法检测合格并符合献血者健康检测其它所有标准者献血不会给自身的安全带来危害,也不会影响血液质量。加之其检测成本较低,硫酸铜比重法在献血者筛查方面仍然有较高的实用价值。当然,对血源紧缺的地区,采用干化学法对比重法不达标者进行复检以提高招募效率也是可行的。     

全血血红蛋白快速检测仪用于献血前检测献血者Hb的评价

目的对用于献血前检测献血者血红蛋白(Hb)的1种全血血红蛋白快速检测仪(Compo Lab TS)做性能评价。方法采用低中高值质控品,使用该仪器检测Hb,评价其精密度;采集29(人)份献血者抗凝血,分别用Compo Lab TS与K-4500血细胞分析仪(简称K-4500)检测Hb,评价两者的相关性;选择日温差较大的10月份,采集2 793(人)份献血者抗凝血,用硫酸铜目测法(硫酸铜法)、Compo Lab TS及K-4500平行检测Hb,评价日温差对试验结果的影响。结果 Compo Lab TS仪器检测Hb低、中、高值的变异系数(r)分别为1. 42%、1. 33%、0. 66%; Compo Lab TS与K-4500检测Hb,两者线性回归方程y=1. 016 9x-0. 1853,r=0. 991 8;硫酸铜法Compo Lab TS和K-4500检测Hb不合格率分别为3. 01%、1. 25%和1. 39%(P0. 01),而Compo Lab TS和K-4500检测Hb不合格率相近(P0. 05)。结论Compo Lab TS血红蛋白检测仪精密度符合要求,与K-4500仪器检测结果相关性较好,与硫酸铜法比较,不受日温差大的影响,可用于献血前Hb的快速初筛。     

微量离心法应用于街头献血者血红蛋白及脂肪血检测

目的探讨微量离心法应用于街头献血者的血红蛋白及脂肪血检测的可行性。方法应用毛细血管专用离心机及全自动血细胞分析仪,分别对600例健康献血者标本进行血细胞比容、血红蛋白浓度及脂肪血检测,检测数据进行统计学处理,界定微量离心法Hct筛查临界值及血浆乳糜程度。结果 Hb与Hct高度正相关,吸取95mm（60μl）末梢血,红细胞压积层≥43.5mm可认为Hb≥120g/L、红细胞压积层≥39mm可认为Hb≥115g/L;脂肪血报废率下降1.4%。结论应用微量离心法同时进行Hct及脂肪血检查,操作简单,无需试剂,仪器小巧便于携带。可用末梢血样,与其他献血前血液检测项目同时采样,不会增加献血者的不适。可替代血站系统目前采用的硫酸铜比重法及献血前咨询来控制血液Hb及乳糜程度检查。     

献血前金标法检测反应性献血者再次献血情况的跟踪评估及策略研究

目的评估对献血前金标法检测反应性献血者进行确证检测及宣教干预措施的效果,推动加强献血者的关爱及促进合格献血者再次参加献血。方法对2013—2018年期间参加无偿献血的初次献血者开展HBsAg和抗-TP金标法检测,对初筛不合格者进行宣教,并在其知情同意的情况下采集静脉血液标本在实验室作确证和补充试验,对确证为阳性者,指导其寻求临床帮助,对阴性或不确定者,宣教后鼓励其再次参加献血。通过采供血信息系统了解这些献血者再次参加献血的情况及筛查的结果,评估干预措施的效果。结果金标法初筛出不合格献血者1 046例(3.57%,1 046/29 338),自愿留取静脉血液样本做确证试验的共138例(13.19%,138/1 046);经健康教育干预后,有48例(4.59%,48/1 046)献血者再次参加无偿献血,其中有32例献血者通过了献血前血液筛检,30例参加了再次献血,14例(29.17%,14/48)献血后检测合格。再次献血时出现HBsAg或抗-TP反应性不合格合计为32例(66.67%,32/48)。金标法阳性确证率可达97.32%(HBsAg,109/112)和85.19%(抗-TP,23/27)。结论加强对金标法初筛不合格献血者的跟踪评估和关爱值得提倡和推广。     

适用于流动采血站的血红蛋白测定新方法

《献血者健康检查要求》(GB18467—2001)中规定献血者在献血时要检查其血液中的血红蛋白(Hb)含量，要求男性≥120g／L；女性≥110g／L。检测Hb含量的方法有硫酸铜比重法或比色法(氰化高铁法或联苯胺法)。虽然比色法灵敏度高、准确性好，但由于需要仪器设备，在流动采血环境中使用不便，因此，目前国内采供血机构在对献血者进行健康检查时均使用硫酸铜比重法。硫酸铜比重法简单、快速，但是，     

血红蛋白目测比色板法在无偿献血初筛中的应用

献血者血红蛋白(Hb)检测．目前多采用硫酸铜溶液比重法，有条件的也用血红蛋白仪检测法，这两种方法，实验室要求较严格，特别是硫酸铜比重法对温度要求高，不适于流动采血车使用。本站于2003年6月引进了由德国CO-PACK公司与世界卫生组织研究开发的血红蛋白目测比色板(HCS)，对献血者Hb初筛检测，笔者同时用血细胞分析仪进行对比试验，现报道如下。     

献血前初次献血者开展乙型肝炎表面抗原和梅毒筛查策略的探讨

目的探讨献血前增加对初次献血者实施乙型肝炎表面抗原(HBs Ag)以及梅毒(TP)筛查策略的效果。方法对上海市奉贤区血站2013年1月1日-2014年12月31日期间,血液筛查HBs Ag和TP检测结果进行了分析,其中对2014年1月-9月时段内的HBs Ag和TP初筛反应性的初次献血者进行了随访留样,并对留样样品以及献血后筛查HBs Ag和TP反应性样品进行了HBs Ag和TP确认。结果初次献血者献血前初筛HBs Ag和TP不合格率分别为3.32%(321/9 679)和0.86%(83/9 679)。对初筛为反应性的献血者征询和留样,HBs Ag和TP阳性确认率分别为98.08%和90.48%。初次献血者经过献血前的血液筛检后,献血后样品仍能检出HBs Ag(0.584%)和TP(0.317%),而重复献血者总阳性率则较初次献血者低。在标准操作流程下,快速法能检出92.4%的HBs Ag反应性献血者和96.9%的TP反应性献血者。结论对初次献血者增加献血前HBs Ag和TP筛查是必要的,可行的。而对重复献血者可不增加该2项检测。     

化学发光法与酶联免疫吸附诊断献血者梅毒螺旋体特异性抗体的价值研究

目的探讨化学发光法(CLIA)与酶联免疫吸附法(ELISA)用于检测献血者梅毒螺旋体(TP)特异性抗体的价值。方法选取2017年1至6月该站无偿献血者献血后存留的血液标本共51 721份,采用CLIA、ELISA、梅毒螺线体颗粒凝集试验(TPPA)进行检测,对于上述3种检测方法检出的阳性标本均进一步用免疫印迹(WB)法进行验证。以WB结果作为"金标准",分析CLIA、ELISA的灵敏度和特异度。结果 CLIA检出阳性患者218例(占0.42%),ELISA法检出阳性患者195例(占0.38%),TPPA法检出阳性患者209例(占0.40%)。3种检测方法检出的阳性率比较差异无统计学意义(P0.05);对上述3种检测结果有差异的61例患者进行TP-WB确认,其中阳性34例,阴性27例,综合分析认为TP特异性抗体阳性214例,阴性51 507例;CLIA对TP特异性抗体检出的灵敏度为100.00%,特异度为99.99%;ELISA对TP特异性抗体检出的灵敏度为84.11%,特异度为99.97%。结论与ELISA比较,CLIA诊断无偿献血者TP特异性抗体有更高的灵敏度和特异度,并且能够实验自动化检测,操作简便,对于无偿献血者大批量血液标本的检测有较大的应用价值。     

Reappraisal of optimal hemoglobin standards for female blood donors in Canada

BACKGROUND: A hemoglobin (Hb) standard of 115 g per L on the copper sulfate test has been in use by the Canadian Red Cross Society Blood Services for female blood donor predonation screening since 1989. STUDY DESIGN AND METHODS: To determine if this lowered Hb standard results in increased iron deficiency in repeat blood donors, a study was conducted to evaluate the performance of the copper sulfate test and predonation capillary and venous Hb assays in a population of female blood donors most at risk of developing iron deficiency. RESULTS: Of the 174 donors who were of childbearing age, who were not taking iron supplements, and who had made at least three blood donations per year, 45 (25.9%) were iron deficient, and 64 (36.8%) had reduced iron stores; only 65 (37.3%) had normal iron stores. This study showed that capillary blood is more likely to have a higher Hb concentration (3.2 +/− 7.8 g/L) than venous blood samples, which could affect the performance of predonation screening assays that are based on capillary blood samples at a given discriminating value. With an Hb standard of 115 g per L, both the copper sulfate and capillary Hb assays were not sensitive enough to screen for iron deficiency (sensitivity, 27% and 33%; specificity, 96% and 93%, respectively) and were comparable only to the performance of a venous Hb assay with a cutoff value of 110 g per L (sensitivity, 27%; specificity, 99%). In contrast, an Hb standard of 125 g per L in the copper sulfate test could achieve a more optimal sensitivity of 79 percent and specificity of 78 percent. CONCLUSION: This study supports the use of a higher Hb cutoff value of 125 g per L for female blood donors in the predonation fingerstick copper sulfate test.     

Reliability of capillary hemoglobin screening under routine conditions

BACKGROUND: Capillary hemoglobin (Hb) measurement before admission for whole blood donation is performed in many blood donation services, in spite of several studies reporting many donors with low Hb values being missed by capillary Hb screening. STUDY DESIGN AND METHODS: Predonation capillary and venous Hb levels of 9209 first‐time donors presenting for whole blood donation were compared. Hb testing was conducted by photometric determination of finger‐stick samples with a photometric method (Donor Checker, HemoCue) and using a hematology analyzer for venous samples. RESULTS: Both capillary and venous Hb measurements were available for 8910 donors (96.8%). The arithmetic mean deviation of the capillary Hb from the venous sample was +1.5 ± 6.8 g/L, and the mean deviation was 5.4 ± 4.5 g/L. In 7865 donors (88%), capillary and venous Hb values differed less than 10 g/L from each other, but in 86 donors (1.0%) the difference was at least 20 g/L, and in 10 donors (0.1%), even 30 g/L or more. In 93.3% of females and 98.7% of males, the categorization as having sufficient or too low Hb for blood donation was concordant between capillary and venous measurements. A total of 34.4% of donors with too low results of capillary Hb screening had sufficient venous Hb levels. Only one donor (0.01%) passed the capillary Hb screening despite venous Hb values below 110 g/L. CONCLUSION: The currently available methods for capillary Hb screening allow reliable determination of predonation Hb values under routine conditions. Additional venous Hb measurements in donors with too low capillary Hb values might reduce the rate of deferred donors by approximately one‐third.     

Anemia screening in potential female blood donors: comparison of two different quantitative methods

BACKGROUND: Anemia screening before blood donation requires an accurate, quick, practical, and easy method with minimal discomfort for the donors. The aim of this study was to compare the accuracy of two quantitative methods of anemia screening: the HemoCue 201⁺ (Aktiebolaget Leo Diagnostics) hemoglobin (Hb) and microhematocrit (micro‐Hct) tests. STUDY DESIGN AND METHODS: Two blood samples of a single fingerstick were obtained from 969 unselected potential female donors to determine the Hb by HemoCue 201⁺ and micro‐Hct using HemataSTAT II (Separation Technology, Inc.), in alternating order. From each participant, a venous blood sample was drawn and run in an automatic hematology analyzer (ABX Pentra 60, ABX Diagnostics). Considering results of ABX Pentra 60 as true values, the sensitivity and specificity of HemoCue 201⁺ and micro‐Hct as screening methods were compared, using a venous Hb level of 12.0 g per dL as cutoff for anemia. RESULTS: The sensitivities of the HemoCue 201⁺ and HemataSTAT II in detecting anemia were 56 percent (95% confidence interval [CI], 46.1%‐65.5%) and 39.5 percent (95% CI, 30.2%‐49.3%), respectively (p < 0.001). Analyzing only candidates with a venous Hb level lower than 11.0 g per dL, the deferral rate was 100 percent by HemoCue 201⁺ and 77 percent by HemataSTAT II. The specificities of the methods were 93.5 and 93.2 percent, respectively. CONCLUSION: The HemoCue 201⁺ showed greater discriminating power for detecting anemia in prospective blood donors than the micro‐Hct method. Both presented equivalent deferral error rates of nonanemic potential donors. Compared to the micro‐Hct, HemoCue 201⁺ reduces the risk of anemic female donors giving blood, specially for those with lower Hb levels, without increasing the deferral of nonanemic potential donors.     

Hemoglobin and iron indices in nonanemic premenopausal blood donors predict future deferral from whole blood donation

BACKGROUND: Iron deficiency anemia is an important reason for blood donor deferral. We prospectively determined whether screening donors with hemoglobin (Hb) and iron indices before donation can predict subsequent deferral due to anemia. STUDY DESIGN AND METHODS: We recruited premenopausal, eligible (nonanemic) female donors. Hb, ferritin, soluble transferrin receptor (sTfR), and hepcidin were measured, and the sTfR/(log)ferritin (sTfR‐F) index was calculated. After 6 months, the donor database was reviewed and whether donors had returned and undergone successful donation was recorded. RESULTS: Of donors, 59 of 261(22.6%) were iron depleted (ferritin < 15 ng/mL). Iron‐depleted donors had donated more often in the previous year, were younger, and had lower Hb. After a minimum of 6 months, 145 eligible donors had returned; of these 10 (6.9%) were deferred for anemia. Donors who developed anemia had significantly lower Hb, ferritin, and hepcidin and higher sTfR and sTfR‐F at baseline. The area under the receiver operating characteristic curve for Hb as a predictor of deferral was 0.86, and for ferritin was 0.88. Hb of less than 130 g/L and ferritin of less than 10 ng/mL combined had sensitivity 80% and specificity 96% in predicting deferral. CONCLUSION: Screening with Hb and iron indices enables prediction of donors at risk of subsequent anemia and who would most benefit from prevention strategies.     

The new noninvasive occlusion spectroscopy hemoglobin measurement method: a reliable and easy anemia screening test for blood donors

BACKGROUND: The tests used for anemia screening in blood donors are based on fingerstick samples, leading to discomfort and complaints. The aim of this study was to analyze the feasibility of occlusion spectroscopy method in blood banks and to compare the method with fingerstick hemoglobinometer and hemoglobin (Hb) determination on an automatic blood analyzer. STUDY DESIGN AND METHODS: The study enrolled 205 consecutive volunteer blood donors. Samples were collected by fingerstick and venous punction to determine Hb level by a Hemocue Hb201+ (Hb‐F) and automatic blood analyzer (Hb‐V) and compare to the noninvasive Hb determination by occlusion spectroscopy using NBM200 system (Hb‐NI). The percentage errors of Hb‐F and Hb‐NI of all donors as well as stratified by sex, weight, and age levels were compared to Hb‐V as reference values using Wilcoxon signed rank test. RESULTS: The results obtained with Hb‐F showed significant errors (p < 0.001) in the general group as well as when stratified by sex, weight, and age groups, above values obtained with Hb‐V. Hb‐NI showed significant errors only in females (p = 0.026) and weight level of 61 to 70 kg (p = 0.034), below Hb‐V values. CONCLUSIONS: Hb‐NI seems to be a good method in terms of precision and feasibility for anemia screening of blood donors as well as being much more comfortable for donors.     

A noninvasive strategy for screening prospective blood donors for anemia

BACKGROUND: The reliability of capillary hemoglobin (Hb) as an indicator for eligibility to donate blood is discussed controversially. Therefore, a noninvasive alternative with acceptable predictive values was established and evaluated. STUDY DESIGN AND METHODS: Donor candidates were selected according to their Hb level. The first donation was performed 6 weeks after this selection step. A venous blood sample was collected from all donors at the end of their donation and a postdonation Hb determination was performed. Donors with acceptable postdonation Hb values were permitted to donate next time without any predonation Hb measurement. Donors with low postdonation Hb values were permitted to donate only after a venous Hb measurement had shown an acceptable value. Sensitivity and specificity were determined by comparing the gold standard (i.e., venous Hb measurement) with the presented method of Hb estimation for 19,534 donors. RESULTS: Taking the postdonation Hb as an indicator for eligibility saved 97 percent of donors from being tested unnecessarily by capillary Hb measurement. This procedure resulted in a specificity of 92.6 percent and a sensitivity of 37.9 percent for Hb cutoff levels of 135 and 125 g per L for men and women, respectively. The sensitivity increased rapidly to 100 percent for Hb levels below 105 g per L. The average deviation from true Hb level was 6 g per L. CONCLUSION: The presented noninvasive method distinctly saves time and expenditure without endangering blood donors.     

Selection of whole-blood donors for hemoglobin testing by use of historical hemoglobin values

BACKGROUND: Usually, a predonation hemoglobin (Hb) measurement must precede blood donation. Hb values of a donor's previous donation might be used for selecting a subgroup in which predonation Hb measurements are unnecessary. STUDY DESIGN AND METHODS: Only donors with historical Hb values below 129 or 139 g per L for female and male donors, respectively, underwent venous Hb measurement before phlebotomy with an automated hematology analyzer. All other donor phlebotomies were collected without initial Hb testing. Hb values from diversion samples from 81,913 consecutive donors between May 2003 and November 2005 were subsequently analyzed as representing their present values. Donors were grouped according to interdonation intervals of less than 6, 6 to 11, 12 to 23, and 24 months or more. RESULTS: The arithmetic mean deviation between historical and present Hb values was between -0.3 and +1.8 g per L for each group (mean deviation, 5.2-6.7 g/L). Not testing selected donors spared 77.7 percent from a prephlebotomy Hb measurement and showed a specificity of 29 percent. Sensitivities for detection of donors below Hb limits (between 56% and 67% for the different subgroups) and donors with Hb values below 110 g per L (82%-88%) were at least comparable to capillary Hb screening. A total of 4.8 percent of donors were phlebotomized with values below 125 and 135 g per L, whereas only 0.016 percent of donors were bled despite Hb levels below 110 g per L. CONCLUSION: Selecting donors for a current Hb measurement based upon their last whole-blood predonation Hb value is a useful method, even after prolonged interdonation intervals.     

Evaluation of hemoglobin of blood donors deferred by the copper sulphate method for hemoglobin estimation.

INTRODUCTION: The copper sulphate (CuSO4) specific gravity test for Hb screening tends to give inappropriate failures. This prompted us to compare it with alternate screening methods. AIM: To study the impact of inaccuracy of CuSO4 method on donor deferral. METHODS: Capillary and venous blood samples of 400 potential blood donors failing the primary Hb screening using appropriately standardized CuSO4 test (specific gravity 1.053) were tested by Hemocue photometer, the Hb colour scale, Cyanmethemoglobin method as well as the automated hematology analyser, which was considered as the standard reference method. RESULTS: One hundred and sixteen donors (29%) who failed the CuSO4 test had true Hb levels >12.5 g/dl. The Hb levels of 131 (32.8%) deferred donors were between 12 and 12.5 g/dl. The sensitivity of Hemocue, Hb colour scale and Cyanmethemoglobin was 99%, 97% and 96% and their specificity was 45%, 93% and 46%, respectively. The positive predictive values (PPV) of Hemocue and Cyanmethemoglobin methods were low (43% and 44%, respectively) but their negative predictive values (NPV) were high (99%, and 97%, respectively). The Hb colour scale had an overall best performance with a PPV of 96% and NPV of 95%. CONCLUSION: The Hemoglobin colour scale which is inexpensive, convenient for field testing and has the overall best performance, is the most suitable for donor Hb screening. Since its readability is 12 g/dl, lowering the donor Hb threshold to 12 g/dl should be actively considered.     

Evaluation of four rapid methods for hemoglobin screening of whole blood donors in mobile collection settings.

INTRODUCTION: Predonation hemoglobin measurement is a problematic requirement in mobile donation settings, where accurate determination of venous hemoglobin by hematology analyzers is not available. OBJECTIVE: We have evaluated hemoglobin screening in prospective donors by the semiquantitative copper sulphate test and by capillary blood samples analyzed by three portable photometers, HemoCue, STAT-Site((R)) MHgb, and the CompoLab HB system. METHODS: Capillary blood samples were obtained from 380 donors and tested by the copper sulphate test and by at least one of the named portable photometers. Predonation venous hemoglobin was also determined in all donors using a Coulter Max-M analyzer. RESULTS: The three photometers provided acceptable reproducibility (CV below 5%), and displayed a significant correlation between the capillary blood samples and the venous hemoglobin (R(2) 0.5-0.8). HemoCue showed the best agreement with venous hemoglobin determination, followed by STAT-Site((R)) MHgb, and the CompoLab HB system. The copper sulphate test provided the highest rate of donors acceptance (83%) despite unacceptable hemoglobin levels, and the lowest rate for donor deferral (1%) despite acceptable hemoglobin levels. The percentage of donors correctly categorized for blood donation by the portable hemoglobinometers was 85%, 82%, and 76% for CompoLab HB system, HemoCue and STAT-Site((R)), respectively. CONCLUSION: Our data suggest that hemoglobin determination remains a conflictive issue in donor selection in the mobile setting. Without appropriate performance control, capillary hemoglobin screening by either the copper sulphate method or by the novel portable hemoglobinometers could be inaccurate, thus potentially affecting both donor safety and the blood supply.     

献血前快速检测谷丙转氨酶的意义

目的 探讨谷丙转氨酶的快速检测对献血者采血前进行初筛的意义.方法 采用干式化学法对献血者进行初筛,同时用生化分析仪复查检测结果并进行比较分析.结果 7 500例献血者中,初筛组(5 000例)采血后谷丙转氨酶复检阳性率为0.1%,未初筛组(2 500例)复检阳性率4.75%,两者差异有统计学意义(χ2=453,P<0.05).同时采用2种方法检测的22例标本,将其结果进行比较,两者差异无统计学意义(P>0.05).结论 对无偿献血者献血前采用快速检测谷丙转氨酶,可大大降低采血后谷丙转氨酶的不合格率,且节约检验成本.